Seven Bridge Financial Group, LLC Glycomimetics Inc Transaction History

Seven Bridge Financial Group, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Oct 09, 2019	SELL	$2.8 - $12.85 $1,400 - $6,425	-500 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$16.06 - $25.35 $8,029 - $12,675	500 New	500 $8,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Seven Bridge Financial Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Seven Bridge Financial Group, LLC with notifications on news.